Denmark news - the latest biotech news from Labiotech.eu

Home Denmark Page 6

Latest Posts

orphazyme rare disease lysosome DNA

Interview 28 Nov 2018

Navigating the Rare Disease Space: Insights from a Danish CEO

Developing drugs for rare diseases is a tough nut for biotech companies to crack. Labiotech’s Helen Albert interviewed the CEO of the Danish company Orphazyme, Anders Hinsby, at the recent BIO-Europe conference in Copenhagen, who told her about the appeals and challenges of making it in the rare disease space. Traditionally, the low number of […]

November 28, 2018 - 5 minutesmins - By Jonathan Smith

leo pharma pellepharm skin cancer

News and Trends 21 Nov 2018

Leo Pharma Enters Partnership to Develop Topical Treatment for Rare Skin Cancer

The Danish company Leo Pharma and the US biotech PellePharm have joined forces to develop a topical treatment for rare forms of skin cancer. In the partnership, dermatology specialist Leo Pharma is paying PellePharm €61M. This is to fund a Phase III trial of PellePharm’s topical drug to treat the skin cancer Gorlin syndrome, which has no […]

November 21, 2018 - 2 minutesmins - By Jonathan Smith

denmark biotech industry

Interview 20 Nov 2018

Why Denmark Is a Strong Player in Europe’s Biotech Industry

Denmark is a rapidly growing hotspot for biotech. During the BIO-Europe conference in Copenhagen, I talked to Mette Kirstine Agger, Managing Partner at the life sciences investor Lundbeckfonden Ventures, to learn more about how the industry is evolving in Europe and Denmark. The US has traditionally been the leader in biotech, but that seems to […]

November 20, 2018 - 4 minutesmins - By Clara Rodríguez Fernández

genmab blood cancer antibody

News and Trends 31 Oct 2018

Multiple Myeloma Antibody Therapy Achieves Positive Phase III Results

An antibody therapy for the blood cancer multiple myeloma achieved positive results at Phase III, decreasing the risk of the disease getting worse and patient death by 45% in a Phase III trial. The blockbuster antibody daratumumab, developed by Janssen using a license from the Danish company Genmab, was given to patients in combination with […]

October 31, 2018 - 2 minutesmins - By Jonathan Smith

Galecto lung disease fibroblasts header

News and Trends 26 Oct 2018

Danish Biotech Closes €79M Series C to Develop Inhaled Lung Disease Drug

The Danish company Galecto Biotech can breathe a contented sigh. Its Series C funding round has raised €79M to finance a Phase II/III trial of its inhaled drug for a deadly lung disease. The amount raised is 30% higher than the company’s initial €60M goal, Galecto’s CEO, Hans Schambye, told me. “Being able to raise […]

October 26, 2018 - 2 minutesmins - By Jonathan Smith

Antivenom Black Mamba Header Edited

News and Trends 5 Oct 2018

Lab-Grown Antivenom Shows Potential for Curing Black Mamba Snakebite

Antivenoms could one day be made in the lab instead of in animals. Researchers from the Technical University of Denmark have neutralized black mamba venom in mice with lab-grown human antibodies for the first time. Snakebite is a serious problem, causing the deaths of around 100,000 people every year, and about three times that number […]

October 5, 2018 - 3 minutesmins - By Jonathan Smith

ADVERTISEMENT

Type 1 Diabetes AG019

News and Trends 10 Sep 2018

Update: Non-Invasive Glucose Monitoring Device Moves Forward With Series B Funding

Update (10/09/2018): RSP Systems has raised an additional €3.85M that raises the total amount of its Series B fundraising to €10.35M. The funds will be used to run clinical trials with the company’s device, which measures blood sugar without the need for finger-pricking. Published on 11/06/2018 RSP Systems has raised €6.5M in the first closing […]

September 10, 2018 - 2 minutesmins - By Alexander Burik

Genmab Cancer Immunotherapy Cover

News and Trends 12 Jul 2018

Collaboration Worth Over €1Bn Could Give Rise to New Cancer Immunotherapies

Genmab is partnering with the German company Immatics to develop immunotherapies directed against three cancer targets. Genmab has offered Immatics, based in Tuebingen, Germany, an upfront payment of $54M (€46M) in addition to milestone payments worth up to $550M (€470M) for each product. Genmab has a market cap of €60Bn ($70Bn). The funding will be […]

July 12, 2018 - 2 minutesmins - By Alexander Burik

Mouth Patch Cover

News and Trends 25 Jun 2018

A Biodegradable Plaster Could Help us Treat Mouth Ulcers

British researchers and a Danish biotech have joined forces to develop a polymer patch that can treat mouth ulcer patients with long-term steroid release and make the wound-healing process faster. Dermtreat, based in Copenhagen, and researchers from the University of Sheffield’s School of Clinical Dentistry in the UK made a patch from polymers that stick […]

June 25, 2018 - 2 minutesmins - By Alexander Burik

Obesity

News and Trends 11 Jun 2018

Danish Biotech Plans Phase II Study to Fight A Rare Eating Disorder

Saniona, a biotech focused on ion channel research, plans to test its lead candidate in a Phase IIa study for the rare eating disorder hypothalamic obesity. Saniona, based in Copenhagen, plans to start a Phase IIa trial testing its product, Tesomet, a combination of tesofensine and metoprolol, in hypothalamic obesity. The study would complement the […]

June 11, 2018 - 2 minutesmins - By Alexander Burik

Genmab Daratumumab Cover Image

News and Trends 28 May 2018

Genmab and Janssen Suffer Combination Therapy Setback

Janssen will discontinue a Phase I study testing Danish biotech Genmab’s blood cancer blockbuster daratumumab combined with a candidate checkpoint inhibitor in patients with multiple myeloma. Janssen, which obtained the exclusive global rights to commercialize daratumumab from Genmab in 2012, will also discontinue a Phase Ib/II study of daratumumab in patients with non-small cell lung […]

May 28, 2018 - 2 minutesmins - By Alexander Burik

Biosyntia Updated Cover

More News! 23 May 2018

Danish Biotech Raises Series A Round to Advance Microbe Engineering Technology

Biosyntia has raised €4M in Series A financing from Sofinnova Partners to bring its microbe engineering technology closer to commercialization. Biosyntia, based in Copenhagen, has raised €4M in Series A financing to continue developing its biosynthetic selection technology to produce complex compounds by fermentation. The funding was provided by Sofinnova Partners, a new investor and leading European […]

May 23, 2018 - 2 minutesmins - By Alexander Burik

ADVERTISEMENT